Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change

Journal of Clinical Pharmacology

Volumn 50, Issue 7, 2010, Pages 805-815

  Wonkyung, Byon ^a   Ouellet, Daniele ^a   Chew, Marci ^a   Ito, Kaori ^a   Burger, Paula ^a   Pauer, Lynne ^a   Zeiher, Bernhardt ^a   Corrigan, Brian ^a  

^a PFIZER INC   (United States)

Author keywords

Exposure response; Fibromyalgia; NONMEM; Pain; Patient global impression of change; Pregabalin

Indexed keywords

PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; CREATININE; DRUG DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; AGING; ALGORITHM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HALF LIFE TIME; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NONLINEAR SYSTEM; PAIN ASSESSMENT; PHYSIOLOGY; SEXUAL DEVELOPMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADULT; AGING; ALGORITHMS; ANALGESICS; CREATININE; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PAIN MEASUREMENT; SEX CHARACTERISTICS;

EID: 77953764110     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009352187     Document Type: Article

References (38)

1. Goldenberg DL Fibromyalgia. In: Klippel JH, Diepe PA, eds. Rheumatology. St Louis, MO: Mosby Inc ; 1994: 5.16.1-5.16.12.
2. Goldenberg DL Fibromyalgia, chronic fatigue syndrome,and myofascial pain syndrome. Curr Opin Rheumatol. 1993 ; 5: 199-208.
3. Bennett RM Confounding features of the fibromyalgia syndrome: a current perspective of differential diagnosis. J Rheumatol. 1989 ; 16 (Suppl 19). 58-61.
4. Goldenberg DL Fibromyalgia syndrome. JAMA. 1987 ; 257: 2782-2787.
5. Taylor CP, Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel ±2- (alpha2- delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 ; 73: 137-150.
6. Fink K., Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002 ; 42: 229-236.
7. Micheva KD, Taylor CP, Smith SJ Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 ; 70: 467-476.
8. Dooley DJ, Donovan CM, Pugsley TA Stimulus-dependent modulation of [3H]-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000 ; 295: 1086-1093.
9. Dooley DJ, Mieske CA, Borosky SA Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000 ; 280: 107-110.
10. Fehrenbacher JC, Taylor CP, Vasko MR Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003 ; 105: 133-141.
11. Dooley DJ, Taylor CP, Donevan S., Feltner D. Ca2+ channel ±2 ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007 ; 28: 75-82.
12. Joshi I., Taylor CP Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha(2)-delta subunit reduces neurotransmission in mice. Eur J Pharmacol. 2006 ; 553: 82-88.
13. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheum. 2008 ; 35 (3). 1-13.
14. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008 ; 9 (9). 792-805. 2008 Jun 3 [Epub ahead of print].
15. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 ; 52: 1264-1273.
16. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008 ; 136 (3). 419-431.
17. Bockbrader HN, Hunt T., Strand J., et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies. Neurology. 2000 ; 54 (suppl 3). 421.
18. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003 ; 43: 277-283.
19. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004 ; 45 (Suppl 6). 13-18.
20. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 ; 52: 1264-1273.
21. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheum. 2008 ; 35 (3). 1-13.
22. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008 Jun 2 [Epub ahead of print].
23. Pauer L., Danneskiold-Samsoe B., Jespersen A., et al. Pregabalin for management of fibromyalgia (FM): A 14-week, randomized, double-blind, placebo-controlled, monotherapy trial (Study A0081100). Ann Rheum Dis. 2008 ; 68 (Suppl II). 256.
24. Wolfe F., Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 ; 33: 160-172.
25. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987 ; 30 (2). 191-197.
26. Beal SL, Sheiner LB Nonmem Users Guide: Part I-VIII. NONMEM Project Group C255. San Francisco University of California at San Francisco ; 1988.
27. Cockroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
28. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). FDA Guidance for Industry on "Population Pharmacokinetics". Washington, DC: Author ; 1999.
29. Bowie MW, Slattum PW Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007 ; 5 (3). 263-303.
30. Hämmerlein A., Derendorf H., Lowenthal DT Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet. 1998 ; 35 (1). 49-64.
31. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I: model development. Anesthesiology. 1997 ; 86 (1). 10-23.
32. Fillingim RB, Gear RW Sex differences in opioid analgesia: clinical and experimental findings. Eur J Pain. 2004 ; 8 (5). 413-425.
33. Gear RW, Miaskowski C., Gordon NC, et al. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996 ; 2: 1248-1250.
34. Gear RW, Miaskowski C., Gordon NC, et al. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 ; 83: 339-345.
35. Buskila D., Neumann L., Alhoashle A., Abu-Shakra M. Fibromyalgia syndrome in men. Semin Arthritis Rheum. 2000 ; 30 (1). 47-51.
36. Wolfe F., Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthr Rheum. 1990 ; 33 (2). 160-172.
37. Turk DC, Rudy TE, Sorkin BA Neglected topics in chronic pain treatment outcome studies: determination of success. Pain. 1993 ; 53 (1). 3-16.
38. Lyrica prescribing information. Available at: http://www.lyrica.com/ content/main-prescribing-info.jsp. Accessed October 24, 2009.